Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
2d
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials of its experimental schizophrenia drug, emraclidine, showed no significant ...
Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback